Skip to main content

Table 2 In-hospital events and treatment strategy

From: Clinical outcomes associated with catecholamine use in patients diagnosed with Takotsubo cardiomyopathy

Variables

No catecholamines

(n = 93)

catecholamines

(n = 21)

p value*

Life-threatening arrhythmia

6 (6.45)

7 (33.33)

< 0.01

NPPV and intubation

21 (22.5)

18 (85.7)

< 0.01

Resuscitation

3 (3.22)

6 (28.57)

< 0.01

Defibrillator-Implantation

1 (1.0)

1 (4.7)

0.33

VA-ECMO

0 (0)

1 (4.7)

0.18

Admission to ICU, length of stay

3.24 ± 3.59

9.57 ± 11.32

< 0.01

In-hospital death

3 (3.2)

6 (28.5)

< 0.01

Thromboembolic events

10 (10.75)

4 (19.04)

0.29

Acquired Long QTs

61 (65.59)

12 (57.14)

0.41

Cardiogenic Shock

4 (4.30)

18 (85.71)

< 0.01

  1. *p values for the comparison between no catecholamines and catecholamines; NPPV Noninvasive positive pressure ventilation, VA-ECMO Veno-arterial extracorporal membrane oxygenation, ICU Intermediate care unit
  2. The bolded indication highlight significant values